Illumina has appointed Richard Klausner to senior vice president and Chief Medical Officer, where he will lead Illumina's strategies for advancing genomics into clinical medicine and public health.
Preivously, Klausner was managing partner of the Column Group, a venture capital firm. He has also served as executive director of the Bill and Melinda Gates Foundation, director of the National Cancer Institute, chief of the cell biology and metabolism branch of the National Institute of Child Health and Human Development, and is a past president of the American Society of Clinical Investigation.
He holds an MD from Duke Medical School.
Gregory Lucier has been appointed to the board of directors at RainTree Oncology .
Lucier is CEO and chairman of Life Technologies. He also serves on the boards of CareFusion Corporation, Synthetic Genomics, and Rady Children's Hospital. He holds a BS in engineering from Pennsylvania State University and an MBA from Harvard Business School.
SynapDx has appointed Mark DePristo to vice president of informatics. DePristo joins the company from the Broad Institute where he served as co-director of medical and population genetics. His team at the Broad created the Genome Analysis Toolkit. He holds a PhD in biochemistry from Cambridge University and a BA in computer science and mathematics from Northwestern University.